Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Pegilodecakin Pre-filled Syringe Versus Vial in Healthy Subjects
NCT04194892Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ilodecakin (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Drug Concentration, Time of Maximum Concentration and 1 more. Started Jan 2018; status: completed.
02
Drugs
ilodecakin
Beyond the preview
Go deeper on NCT04194892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194892.